Dosimetric analysis of trigeminal nerve, brain stem doses in CyberKnife radiosurgery of trigeminal neuralgia

H. Sudahar, P. G. G. Kurup, V. Murali, J. Velmurugan

Department of Radiotherapy, Apollo Speciality Hospital, 1Department of Medical Physics, Anna University, Chennai, India

Received on: 28.01.12 Review completed on: 30.03.12 Accepted on: 19.04.12

ABSTRACT

CyberKnife radiosurgery treatment of Trigeminal neuralgia (TN) is performed as a non-invasive image guided procedure. The prescription dose for TN is very high. The brainstem is the adjacent critical organ at risk (OAR) which is prone to receive the very high target dose of TN. The present study is to analyze the dose distribution inside the tiny trigeminal nerve target and also to analyze the dose fall off in the brain stem. Seven TN cases treated between November 2010 and January 2012 were taken for this study retrospectively. The treatment plans were analyzed for target dose conformity, homogeneity and dose coverage. In the brainstem the volume doses D1%, D2% were taken for analyzing the higher doses in the brain stem. The dose fall off was analyzed in terms of D5% and D10%. The mean value of maximum dose within the trigeminal nerve target was 73.5±2.1Gy (P=0.0007) and the minimum dose was 50.0±4.1Gy (P=0.1315). The mean conformity index was 2.19 and the probable reason could be the smallest CyberKnife collimator of 5mm used in the treatment plan. The mean D1% of the brainstem was 10.5±2.1Gy (P=0.5316) and the mean value of the maximum point dose within the brainstem was 35.6±3.8Gy. This shows the degree of dose fall off within the brainstem. Though the results of the present study are showing superior sparing of brain stem and reasonable of target coverage, it is necessary to execute the treatment plan with greater accuracy in CyberKnife as the immobilization is noninvasive and frameless.

Key words: Brainstem dose; cyberknife; stereotactic radiosurgery; trigeminal neuralgia

Introduction

Trigeminal neuralgia (TN) is a trigeminal nerve disorder which causes an agonizing facial pain in the affected patients. TN is also called as “suicide disease”[1] and this terminology explains the extent of pain in patients. The cause for TN is the focal demyelination of trigeminal nerve root by vascular compression.[2] Generally, TN occurs unilaterally; however, occasionally may be bilateral. [3] There are three main treatment modalities for TN: medical treatments through drugs, surgical treatment and radiosurgery treatment.[4-7] Micro-vascular decompression (MVD) is a well-known surgical treatment for TN.[8,9] Radiosurgery for TN has been performed either as a frame based or as a frameless radiosurgery. Frame based is an invasive method while frameless is a noninvasive method. Leksell Gamma Knife (Elekta Instruments, Norcross, GA)[10,11] radiosurgery is a frame based procedure, while CyberKnife (Accuray, Sunnyvale, USA)[12,13] is an image guided frameless procedures. In the BrainLAB Novalis (BrainLAB A.C., Heimstetten, Germany)[14,15] radiosurgery system, both the frame based and frameless procedures are being performed. The radiation dose required to treat TN is very large when compared with all other radiosurgical procedures performed in the cranium.

The dose in Gamma Knife is often prescribed to a 50% isodose, and the prescription dose is between 35 Gy to 40 Gy.[16] A maximum of 70 Gy to 90 Gy is delivered to the trigeminal nerve in Gamma Knife.[17] Similarly in
CyberKnife, the dose is prescribed to 75% to 85% isodose and the prescription dose is 60 Gy. This very high dose prescription to the very tiny trigeminal nerve necessitates very precise targeting. Especially, the organs at risk (OAR) doses should be restricted to their tolerance limit. Brainstem is the critically closer OAR to the trigeminal nerve in the treatment of TN. Treatment planning plays a crucial role in restricting the dose to the brainstem. In CyberKnife, the treatment planning is performed in a dedicated planning system called Multiplan (Accuray, Sunnyvale, USA). There are many numbers of studies on the clinical outcomes of the radiosurgical treatment of TN. However, there are only a limited number of studies available on the dose distribution in and around the trigeminal nerve in the radiosurgery of TN, especially in the cyberknife radiosurgery. The present study aims to analyze the dose distribution in the trigeminal nerve and in the brainstem in cases treated with CyberKnife stereotactic radiosurgery system.

### Materials and Methods

Seven TN cases treated between November 2010 and January 2012 were taken retrospectively for this study. Out of these seven cases, four were cases of TN in the left side, and three were of TN in the right side. Four of them were males and three were female patients. The median age and the mean age were 61 and 57.2 years, respectively.

#### Target and organs at risk delineation

Visualization of the trigeminal nerve is an important task in TN treatment. The Computed Tomography (CT) images of the cranium were acquired in 1 mm slice thickness. These CT images were fused accurately with a special T2 weighted Drive sequence magnetic resonance (MR) images [Figure 1]. With the help of these T2 Drive MR images, the trigeminal nerve and the OARs were drawn on the fused CT images. The target was drawn in such a way that the target segment of the trigeminal nerve starts from 2 to 3 mm away from the root entry zone (REZ). The length of the target segment in the trigeminal nerve was delineated for about 6 mm in 3 CT slices of 1 mm thickness.

#### Treatment planning

CyberKnife plans are associated with site specific paths which give the information about the beam orientation. A dedicated trigeminal path is also provided for the treatment of TN. The smallest 5 mm fixed type collimator was taken for treating TN. The goal dose to the trigeminal nerve target was set as 60 Gy. The dose gradient around the target was set as a goal in the treatment planning. The 60 Gy dose was limited within a shell of 0.5 mm around the target. Similarly 55 Gy to 2 mm shell, 48 Gy to 5 mm shell and 28 Gy was set to 10 mm shell. The dose constraint for the brainstem was kept as 40 Gy. The maximum dose in the target was taken as the normalizing dose. The plans were made and evaluated.

#### Treatment plan evaluation

The target volume doses $D_{90\%}$, $D_{95\%}$, $D_{98\%}$ and $D_{100\%}$ were evaluated from the dose volume histogram (DVH). The amount of trigeminal nerve target volume receiving 100% of the prescribed dose, $V_{100\%}$, was also evaluated in percentage. The dose conformity index and homogeneity index of the TN target were also analyzed. The formulae used to calculate the conformity index and the homogeneity index are given as follows.

\[
\text{Conformity Index (CI)} = \left( \frac{V_{\text{TN}}}{\text{TV}} \right) \left( \frac{\text{TV}}{V_{\text{TN}}} \right)^2
\]

Where $V_{\text{TN}}$ is the overall volume including the target volume, receiving the prescription isodose or more, TV is the volume of the trigeminal nerve target, and $V_{\text{TN}}$ is the volume of the target which receives the prescription isodose or more. This conformity index was initially proposed in an inverse way by Paddick and modified in the current form by Nakamura et al.

\[
\text{Homogeneity index (HI)} = \frac{D_{\text{max}}}{D_{\text{max}}}^{\text{[20]}}
\]

Where $D_{\text{max}}$ is the maximum dose in the nerve target and $D_{\text{ref}}$ is the reference / prescription isodose. Brainstem doses were evaluated in terms of $D_{10\%}$, $D_{25\%}$, $D_{50\%}$ and $D_{100\%}$. This low percentage volume doses are representing the higher doses in the brain stem. Along with this, the maximum point doses and the mean doses in the target as well as in the brainstem were also estimated for analysis. The p-values were calculated using two tailed Student’s T-test and tabulated in appropriate tables.

#### Results

The mean volume of the trigeminal nerve target was $37.9 \pm 2.5$ mm$^3$. The minimum volume was $35.4$ mm$^3$ and the maximum volume was $42.3$ mm$^3$. The mean volume of
Table 1: Target dose distribution analysis in terms of volume doses

| Study number | Target volume (mm³) | Volume doses of the trigeminal nerve target (Gy) |
|--------------|---------------------|-----------------------------------------------|
|              |                     | D₉₈% | D₉₀% | D₅₀% | D₃₀% | D₁₀% |
| Case 1       | 37.8                | 53.3  | 54.8  | 64.5  | 67.5  | 72.0  |
| Case 2       | 40.3                | 52.9  | 57.2  | 63.5  | 66.4  | 67.1  |
| Case 3       | 42.3                | 49.5  | 51.8  | 65.3  | 69.8  | 74.3  |
| Case 4       | 36.6                | 56.5  | 58.6  | 64.2  | 66.4  | 68.5  |
| Case 5       | 36.6                | 45.0  | 53.3  | 63.8  | 66.8  | 72.0  |
| Case 6       | 35.4                | 53.3  | 54.8  | 63.0  | 65.3  | 71.3  |
| Case 7       | 36.6                | 52.0  | 56.3  | 63.7  | 66.6  | 70.2  |
| Mean ± Standard deviation | 37.9 ± 2.5 | 51.8 ± 3.6 | 55.3 ± 2.3 | 64.0 ± 0.7 | 66.9 ± 1.4 | 70.8 ± 2.4 |

P value | 0.0665 | 0.0863 | 0.0092 | 0.0000 | 0.0001 | 0.0025 |

Table 2: Target dose distribution analysis in terms of mean dose, minimum and maximum point doses

| Study number | Trigeminal nerve target doses (Gy) | Minimum | Maximum | Mean |
|--------------|------------------------------------|---------|---------|------|
| Case 1       | 52.5                               | 75.0    | 63.9    |
| Case 2       | 52.4                               | 70.6    | 63.3    |
| Case 3       | 48.8                               | 75.0    | 64.2    |
| Case 4       | 55.5                               | 70.6    | 64.0    |
| Case 5       | 42.7                               | 75.0    | 62.9    |
| Case 6       | 48.7                               | 75.0    | 63.0    |
| Case 7       | 49.5                               | 73.2    | 63.2    |
| Mean ± Standard deviation | 50±4.1 | 73.5±2.1 | 63.5±0.5 |

P value | 0.1315 | 0.0007 | <0.0001 |

Figure 2: Dose distribution in the axial plane in a sample case

Figure 3: Dose distribution in the sagittal plane in a sample case

Figure 4: Dose distribution in the coronal plane in a sample case

the brainstem was 22 ± 4.7 cm³. The dose distributions in the axial, sagittal and coronal sections in the MR images are shown in Figure 2, Figure 3 and Figure 4 respectively.

Analysis of the trigeminal nerve target dose

The D₉₈%, D₉₀%, D₅₀%, D₃₀% and D₁₀% values of the trigeminal nerve target are shown in Table 1. D₉₈% is a measure of the minimum dose within the trigeminal nerve target. The mean value of D₉₈% was 51.8 ± 3.6 Gy. The maximum and the minimum values of D₉₈% were 56.5 Gy and 45.0 Gy, respectively. Similarly, D₉₀% is the measure of maximum dose within the trigeminal target. D₉₀% was ranging between 67.1 Gy and 74.3 Gy. The mean value was 70.8 ± 2.4 Gy. The percentage volume of the trigeminal nerve target receiving 100% of the prescribed dose, V₁₀₀%, was
75.8 ± 4.6%. The mean values of CI and the HI were 2.19 ± 0.32 and 1.2 ± 0.03, respectively. The mean value of the prescribing isodose was 81.7 ± 2.4%. The conformity and homogeneity indices, the prescribing isodose and $V_{100}$ are shown in Table 2. Minimum, maximum point doses and the mean doses in the target are shown in Table 3. The mean maximum dose was 75.5 ± 2.1 Gy and this maximum point dose was varying between 70.6 Gy and 75 Gy. Similarly the mean value of the minimum point dose was 50.0 ± 4.1 Gy and range of the minimum point dose in the trigeminal nerve target was from 42.7 Gy to 55.5 Gy.

**Analysis of the brainstem dose**

The $D_{1\%}$, $D_{2\%}$, $D_{5\%}$ and $D_{10\%}$ values of the OAR brainstem are shown in Table 4. The mean brainstem dose and the maximum point dose in the brainstem are also shown in Table 4. The volume doses $D_{1\%}$ and $D_{2\%}$ are representing the maximum doses in the brainstem, while $D_{5\%}$ and $D_{10\%}$ are representing the degree of dose fall off in the brainstem. The mean values of $D_{1\%}$, $D_{2\%}$, $D_{5\%}$ and $D_{10\%}$ were 10.5 ± 2.1 Gy, 7.9 ± 1.8 Gy, 5.1 ± 1.7 Gy and 3.3 ± 1.3 Gy respectively. The maximum point dose was varying between 29.4 Gy and 40.0 Gy and the mean value was 35.6 ± 3.8 Gy.

**Discussion**

The maximum dose to the target segment of the trigeminal nerve is a matter of concern in the radiosurgical treatment of TN. In Gamma Knife radiosurgery of TN, the maximum dose often crosses 85 Gy. However in CyberKnife radiosurgery for TN, the reported maximum doses are well within 80 Gy. Adler et al. is reporting a maximum trigeminal nerve target dose in CyberKnife radiosurgery as 73.5 Gy which matches with the present study. The mean value of the maximum dose in the present study is 73.5 ± 2.1 Gy. Study by Villavicencio et al. shows a median maximal dose to the trigeminal nerve of 78 Gy. Though there is a difference in the maximum dose between the Gamma Knife radiosurgery and CyberKnife radiosurgery the clinical correlations are showing appreciable success rate in both the cases.

The mean prescribing isodose line in the present study is 81.7% and the mean coverage is 75.8%. This shows that about 24% of the tiny trigeminal target is receiving dose lesser than 60 Gy. But the mean minimum dose of the target is 50.01 ± 4.06 Gy. Hence the trigeminal nerve target is in the range of ~50 Gy to ~73.5 Gy. However the mean conformity index is 2.19. This shows that there is an equal volume of normal tissue surrounding the target equal to the volume of the target is receiving the prescribing dose. This is mainly because of the size of the target and this TN target is possibly the smallest target among all the targets treated in radiosurgery. Also the minimum size of the collimator available in CyberKnife is 5 mm. The width of the TN nerve target in any of CT slice containing the target is about 2 mm only. These are the possible reason for the higher value of conformity index in radiosurgery treatment of TN. The mean value of the homogeneity index is 1.23 which

| Study number | Conformity index | Homogeneity index | Prescribing isodose (%) | $V_{100}$ (%) |
|--------------|------------------|-------------------|-------------------------|--------------|
| Case 1       | 2.08             | 1.25              | 80                      | 72.6         |
| Case 2       | 2.15             | 1.18              | 85                      | 72.7         |
| Case 3       | 2.01             | 1.25              | 80                      | 75.8         |
| Case 4       | 2.55             | 1.18              | 85                      | 81.7         |
| Case 5       | 1.87             | 1.25              | 80                      | 70.0         |
| Case 6       | 2.73             | 1.25              | 80                      | 75.9         |
| Case 7       | 2.00             | 1.22              | 82                      | 82.0         |
| Mean ± Standard deviation | 2.19 ± 0.32 | 1.23 ± 0.03 | 81.7 ± 2.4 | 75.8 ± 4.6 |
| $P$ value    | 0.3795           | 0.0005            | 0.0008                  | 0.0517       |

| Serial number | Brainstem volume (cc) | $D_{1\%}$ | $D_{2\%}$ | $D_{5\%}$ | $D_{10\%}$ | Maximum | Mean |
|---------------|-----------------------|-----------|-----------|-----------|-----------|---------|------|
| Case 1        | 24.01                 | 7.50      | 6.00      | 3.75      | 3.00      | 35.06   | 1.42 |
| Case 2        | 26.24                 | 12.71     | 9.88      | 6.35      | 4.24      | 29.37   | 2.01 |
| Case 3        | 16.65                 | 12.75     | 9.75      | 6.75      | 4.50      | 32.42   | 2.50 |
| Case 4        | 28.69                 | 9.88      | 7.76      | 5.65      | 3.53      | 37.51   | 1.93 |
| Case 5        | 18.77                 | 9.00      | 6.00      | 2.25      | 0.75      | 35.65   | 6.85 |
| Case 6        | 16.86                 | 9.00      | 6.75      | 4.50      | 3.00      | 39.52   | 1.50 |
| Case 7        | 22.87                 | 12.44     | 9.51      | 6.59      | 4.39      | 39.99   | 1.75 |
| Mean ± Standard deviation | 22.0 ± 4.7 | 10.5 ± 2.1 | 7.95 ± 1.75 | 5.12 ± 1.69 | 3.34 ± 1.31 | 35.65 ± 3.81 | 2.57 ± 1.92 |
| $P$ value     | 0.5488                | 0.5316    | 0.5611    | 0.6960    | 0.7412    | 0.2426  | 0.8631 |

Journal of Medical Physics, Vol. 37, No. 3, 2012
shows that the dose variation within the target is about 23% and the mean value of the mean target dose is 63.5 Gy.

The target dose coverage usually lowered because of the dose restriction to the brain stem. The mean value of the $D_{10}$ in the brainstem is 10Gy while the mean maximum point dose in brain stem is 35.6 Gy. The mean value of 1% volume of brainstem is 0.22 ± 0.05 cm³. This shows that the 50% of the prescribed 60 Gy dose (30 Gy) is falling well within this 0.22 cm³ volume of the brain stem which is closer to the trigeminal nerve REZ. The brainstem dose gradient analysis by $D_{5}$, $D_{5}$ and $D_{10}$ are showing a better dose fall off of dose within the brainstem.

**Conclusion**

The target segment of the trigeminal nerve should be irradiated with an adequate dose to reduce the pain due to TN. The present study shows that the point dose maximum in CyberKnife radiosurgery of TN is about 75 Gy. The study also shows that the dose distribution in the tiny target is not limited within the target. The minimal collimator of 5 mm could be the possible reason for this. Though there is a spillage of dose outside the target, it is not towards the critical OAR brainstem. According to the present study, the maximum brainstem point dose is less than 50% of the maximum point dose in the target. Though the results of the present study are showing superior sparing of brain stem and reasonable of target coverage, it is necessary to correlate the dose distribution with the clinical outcomes through follow ups. The effectiveness of the treatment plan exists in the proper execution with greatest accuracy, as the CyberKnife radiosurgery is executed with a noninvasive immobilization.

**References**

1. Adams H, Pendleton C, Latimer K, Cohen-Gadol AA, Carson BS, Quinones-Hinojosa A. Harvey Cushing’s case series of trigeminal neuralgia at the Johns Hopkins Hospital: A surgeon’s quest to advance the treatment of the ‘suicide disease’. Acta Neurochir (Wien) 2011; 153:1043-50.
2. Oh IH, Choi SK, Park BJ, Kim TS, Rhee BA, Lim YJ. The treatment outcome of elderly patients with idiopathic trigeminal neuralgia: Micro-vascular decompression versus gamma knife radiosurgery. J Korean Neurosurg Soc 2008; 44:199-204.
3. Brismar R. Bilateral trigeminal neuralgia. J Neurosurg 1987; 67:44-8.
4. Mendoza N, Illingworth RD. Trigeminal neuralgia treated by microvascular decompression: A long-term follow-up study. Br J Neurosurg 1995; 9:13-9.
5. Brismar R. Surgical treatment of trigeminal neuralgia. Semin Neurol 1997; 17:367-72.
6. Zakrzewska JM, Patsalos PN. Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. Pain 2002; 95:259-66.
7. Obermann M. Treatment options in trigeminal neuralgia. Ther Adv Neurol Disord 2010; 3:107-15.
8. Chakravarthi PS, Ghanta R, Kattimani V. Microvascular decompression treatment for trigeminal neuralgia. J Craniofac Surg 2011; 22:894-8.
9. Sindou M, Leston J, Decullier E, Chapuis F. Microvascular decompression for primary trigeminal neuralgia: Long-term effectiveness and prognostic factors in a series of 362 consecutive patients with clear-cut neurovascular conflicts who underwent pure decompression. J Neurosurg 2007; 107:1144-53.
10. McNatt SA, Yu C, Giannotta SL, Zee CS, Apuzzo ML, Petrovich Z. Gamma Knife radiosurgery for trigeminal neuralgia. Neurosurgery 2005; 56:1295-301.
11. Kondziolka D, Zoro O, Lobato-Polo J, Kano H, Flannery TJ, Flickinger JC, et al. Gamma Knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurgery 2010; 112:758-65.
12. Tang CT, Chang SD, Tseng KY, Liu MY, Ju DT. CyberKnife stereotactic radiosurgical rhizotomy for refractory trigeminal neuralgia. J Clin Neurosci 2011; 18:1449-53.
13. Peddada AV, Secats DJ, White GA, Bulz G, Gibbs GL, Switzer B, et al. CyberKnife radiosurgery for trigeminal neuralgia: Unanticipated iatrogenic effect following successful treatment. J Neurosurg 2011; 115:940-4.
14. Zahra H, Teh BS, Paulino AC, Yoshor D, Trask T, Baskin D, et al. Stereotactic radiosurgery for trigeminal neuralgia utilizing the BrainLAB Novalis system. Technol Cancer Res Treat 2009; 8:407-12.
15. Chen JC, Rahimian J, Rahimian R, Arellano A, Miller MJ, Girvigian MR. Frameless image-guided radiosurgery for initial treatment of typical trigeminal neuralgia. World Neurosurg 2010; 74:538-43.
16. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL. Gamma Knife radiosurgery for trigeminal neuralgia: The initial experience of the Barrow Neurological Institute. Int J Radiat Oncol Biol Phys 2000; 47:1013-9.
17. Henson CF, Goldman HW, Rosenwasser RH, Downes MB, Bednarz G, Pequignot EC, et al. Glycerol rhizotomy versus Gamma Knife radiosurgery for the treatment of trigeminal neuralgia: An analysis of patients treated at one institution. Int J Radiat Oncol Biol Phys 2005; 63:82-90.
18. Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 2000; 93 Suppl 3:219-22.
19. Nakamura JL, Verhey LJ, Smith V, Petti PL, Lamborn KR, Larson DA, et al. Dose conformity of Gamma Knife radiosurgery and risk factors for complications. Int J Radiat Oncol Biol Phys 2001; 51:1313-9.
20. Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, et al. Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 1993; 27:1231-9.
21. Sheehan J, Pan HC, Stroila M, Steiner L. Gamma Knife surgery for trigeminal neuralgia: outcomes and prognostic factors. J Neurosurg 2005; 102:434-41.
22. Pollock BE, Phuong LK, Foote RL, Stafford SL, Goman DA. High-dose trigeminal radiosurgery associated with increased risk of trigeminal nerve dysfunction. Neurosurgery 2001; 49:58-62.
23. Adler JR Jr, Bower R, Gupta G, Lim M, Efron A, Gibbs GC, et al. Nonisocentric radiosurgical rhizotomy for trigeminal neuralgia. Neurosurgery 2009; 64:484-90.
24. Villavicencio AT, Lim M, Bumeneikey S, Romanelli P, Adler JR, McNeeley L, et al. CyberKnife radiosurgery for trigeminal neuralgia treatment: A preliminary multicenter experience. Neurosurgery 2008; 62:647-55.
25. Fariselli L, Marras C, De Santis M, Marchetti M, Milanesi I, Broggi G. CyberKnife radiosurgery as a first treatment for idiopathic trigeminal neuralgia. Neurosurgery 2009; 64:A96-101.

**How to cite this article:** Sudahar H, Kurup P, Murali V, Velmurugan J. Dosimetric analysis of trigeminal nerve, brain stem doses in CyberKnife radiosurgery of trigeminal neuralgia. J Med Phys 2012;37:124-8.

**Source of Support:** Nil, Conflict of Interest: None declared.